One To Watch
Nuvalent
A clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer.
Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
Latest Nuvalent News
18 November 2025
6 November 2024
11 July 2024
Today's issue
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze